Zoloev G K, Slepushkin V D, Argintaev E S, Prum I A, Sokolovich G E
Biull Eksp Biol Med. 1989 Oct;108(10):468-70.
The experiments have been performed on 70 male rats weighing 200-250 gr., 53 patients with obliterating atherosclerosis of lower extremities have been examined. Leu-enkephalin analogues (dalargin and DEFN) administration in a dose of 0.1 mg/kg has been determined to decrease cholesterol levels in the blood in acute and chronic experimental hypercholesterolemia. The use of pharmacological preparation -- enkephalin analogue of dalargin in complex treatment of the obliterating atherosclerosis of lower extremities leads to cholesterol concentration decrease, parathormone concentration decrease in the blood of patients and hyperlactatemia decrease in venous blood of the damaged extremity. Leu-enkephalin analogues, action mechanisms and the possibility of their use for atherosclerosis treatment is discussed.
实验在70只体重200 - 250克的雄性大鼠身上进行，对53例下肢闭塞性动脉粥样硬化患者进行了检查。已确定以0.1毫克/千克的剂量给予亮氨酸脑啡肽类似物（达洛啡肽和DEFN）可降低急性和慢性实验性高胆固醇血症中的血液胆固醇水平。在下肢闭塞性动脉粥样硬化的综合治疗中使用药物制剂——达洛啡肽的脑啡肽类似物，可使患者血液中的胆固醇浓度降低、甲状旁腺激素浓度降低，并使受损肢体静脉血中的高乳酸血症降低。文中讨论了亮氨酸脑啡肽类似物、其作用机制以及用于动脉粥样硬化治疗的可能性。
